Publicacións (15) Publicacións de Elena Yaiza Romero Ventosa

2022

  1. Descripción y cuantificación de las intervenciones farmacoterapéuticas al ingreso de los pacientes en un centro sociosanitario

    Pharmaceutical care España, Vol. 24, Núm. 1, pp. 20-32

  2. Regorafenib and trifluridine/tipiracil in real clinical practice

    Journal of cancer research and therapeutics, Vol. 18, pp. S367-S373

2021

  1. Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice

    Clinical Therapeutics, Vol. 43, Núm. 4, pp. e111-e121

2020

  1. Standardization Consensus of a Hospital Drug Database: An Efficient Tool

    Therapeutic Innovation and Regulatory Science, Vol. 54, Núm. 1, pp. 85-92

2019

  1. Experience with nebulised colistin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 3, pp. 217-223

2018

  1. Conciliación de medicación al alta hospitalaria: colaboración entre farmacéuticos de atención primaria y atención especializada

    Pharmaceutical care España, Vol. 20, Núm. 5, pp. 352-370

  2. Evaluation of the use of nab-paclitaxel and gemcitabine in clinical practice

    Journal of Cancer Research and Therapeutics, Vol. 14, Núm. 10, pp. S730-S735

  3. Pharmacotherapeutic Reports as Tools for Detecting Discrepancies in Continuity of Care

    Therapeutic Innovation and Regulatory Science, Vol. 52, Núm. 1, pp. 94-99

  4. Standardization Consensus of a Hospital Drug Database: An Efficient Tool

    Therapeutic Innovation and Regulatory Science

2017

  1. Effect of tyrosine kinase inhibitors on the glucose levels in diabetic and nondiabetic patients

    Indian Journal of Cancer, Vol. 54, Núm. 1, pp. 136-143

2016

  1. Multidisciplinary teams involved: Detection of drug-related problems through continuity of care

    Farmacia Hospitalaria, Vol. 40, Núm. 6, pp. 529-543

  2. Short stay unit and emergency department: Pharmacotherapeutic interventions and its impact

    American Journal of Therapeutics, Vol. 23, Núm. 6, pp. e1307-e1314

2015

  1. Inmunología e inmunoterapia del cáncer colorrectal

    Abordaje multidisciplinar de cáncer colorrectal (Andavira), pp. 337-356

  2. Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients

    SpringerPlus, Vol. 4, Núm. 1

2012

  1. Efficacy and toxicity of erlotinib in non-small cell lung cancer treatment

    Farmacia Hospitalaria, Vol. 36, Núm. 2, pp. 68-76